Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ala Mortazavi

Pulmonary Disease Woodbridge, VA Medical Doctor

NPI 1306812870 CMS profile 968880

2028 Opitz Blvd., Suite B, Woodbridge, VA 22191

Open in the dashboard

General payments

$4,210

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ala Mortazavi of Woodbridge, VA is reported in the CMS Open Payments database as having received $4,210 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $938 45
2024 General $611 26
2023 General $579 29
2022 General $585 46
2021 General $529 41
2020 General $446 39
2019 General $522 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ala Mortazavi
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ala Mortazavi were reported at $938. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ala Mortazavi Pulmonary Disease median Middle half National median
2019 $522 $377 $109–$1,340 $163
2020 $446 $230 $56–$907 $114
2021 $529 $269 $68–$1,072 $132
2022 $585 $390 $100–$1,457 $149
2023 $579 $419 $114–$1,659 $160
2024 $611 $476 $123–$1,818 $164
2025 $938 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,754 77 payments
  2. GlaxoSmithKline, LLC. $1,027 114 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $197 10 payments
  4. Verona Pharma, Inc. $139 8 payments
  5. Genzyme Corporation $117 5 payments
  6. Mallinckrodt Hospital Products Inc. $82 4 payments
  7. ANI Pharmaceuticals, Inc. $79 4 payments
  8. Advanced Respiratory, Inc $73 4 payments
  9. Harmony Biosciences LLC $69 3 payments
  10. Mylan Specialty L.P. $64 4 payments
  11. Other $610 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,187 269 payments
  2. Education $23 1 payment
Products named General payments · program years 2019–2025
  1. BREZTRI $701 29 payments
  2. AIRSUPRA $674 21 payments
  3. TRELEGY ELLIPTA $443 65 payments
  4. FASENRA Respiratory $429 17 payments
  5. NUCALA $367 22 payments
  6. OFEV $267 12 payments
  7. SYMBICORT $226 8 payments
  8. FASENRA Respiratory $197 8 payments
  9. TEZSPIRE $144 1 payment
  10. Ohtuvayre $139 8 payments
  11. Other $1,689 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,890

Median for Pulmonary Disease: 936

Drug cost

$1,080,692

Median for Pulmonary Disease: $487,987

Branded share of claims

81.8%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 852 $677,680
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 179 $127,302
Breo Ellipta Fluticasone/Vilanterol Brand 137 $61,285
Spiriva Respimat Tiotropium Bromide Brand 79 $52,084
Eliquis Apixaban Brand 59 $42,928
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 72 $39,637
Symbicort Budesonide/Formoterol Fumarate Brand 47 $17,381
Albuterol Sulfate Hfa Albuterol Sulfate Brand 650 $13,199
Xarelto Rivaroxaban Brand 12 $11,828
Fluticasone-Vilanterol Fluticasone/Vilanterol Brand 19 $5,499

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$395,632

Of which drugs: $5,874

Medicare patients

1,063

Average age 77

Services billed

4,589

556 women, 507 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 50%
Ischemic heart disease 49%
COPD 49%
Heart failure 40%
Chronic kidney disease 37%
Atrial fibrillation 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 19 19 $5,522
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90688 Office 17 17 $348

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $219
$219 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $72
  • Amgen Inc. $27
$99 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $60
$60 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $51
$51 179 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record